{"id":14971,"date":"2019-08-27T16:23:29","date_gmt":"2019-08-27T14:23:29","guid":{"rendered":"https:\/\/www.hollandbio.nl\/?p=14971"},"modified":"2019-08-27T16:23:30","modified_gmt":"2019-08-27T14:23:30","slug":"20med-therapeutics-and-partners-receive-eurostars-grant-for-the-development-of-new-mrna-therapeutics-for-osteoarthritis","status":"publish","type":"post","link":"https:\/\/www.hollandbio.nl\/en\/nieuws\/20med-therapeutics-and-partners-receive-eurostars-grant-for-the-development-of-new-mrna-therapeutics-for-osteoarthritis\/","title":{"rendered":"20MED THERAPEUTICS AND PARTNERS RECEIVE EUROSTARS GRANT FOR THE DEVELOPMENT OF NEW MRNA THERAPEUTICS FOR OSTEOARTHRITIS"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>20Med Therapeutics\u00a0<\/strong>announced with its partners\u00a0<strong>Ethris GmbH<\/strong>,\u00a0<strong>the AO Research Institute Davos\u00a0<\/strong>and\u00a0<strong>Paracelsus Medical University\u00a0<\/strong>the receipt of a Eurostars grant to be used to further the development of a novel approach to treating osteoarthritis (OA) by the consortium of companies and institutions. The Eurostars program is managed by the EUREKA organization, which supports highly innovative technologies to bring them closer to the market and is supported by the European Union under the Horizon 2020 Framework Program.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Osteoarthritis, which affects 130 million people worldwide, is characterized by chronic joint pain and functional impairment. OA imposes a huge burden on the individual patient and European health care system. No treatments for OA are available to counteract disease progression. Often total joint replacement is the only therapeutic option.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cWith osteoarthritis predicted to be the fourth leading cause of disability worldwide by 2020 and no approved treatments to counteract disease progression, there is an urgent need for new treatment options,\u201d said Dr. Michiel Lodder, CEO of 20Med Therapeutics. \u201cThe Eurostar grant will support the development of a novel approach to treating osteoarthritis using bioresponsive polymer-based nanoparticle delivery of stabilized mRNA factors into the joint.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The consortium\u2019s novel approach to developing new mRNA therapeutics for OA utilizes 20Med\u2019s unique patented nanotechnology combined with Ethris\u2019 proprietary stabilized non-immunogenic mRNA technology \u2013 SNIM\u00ae. The new therapeutics will be tested in different preclinical models by the consortium partners from Paracelsus Medical University, Salzburg, Austria, and the AO Research Institute Davos (ARI), Switzerland.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Source:  <strong><a href=\"https:\/\/20medtx.com\/news\/joint-approach-pressrelease\/\" target=\"_blank\" rel=\"noreferrer noopener\" aria-label=\"https:\/\/20medtx.com\/news\/joint-approach-pressrelease\/  (opent in een nieuwe tab)\">https:\/\/20medtx.com\/news\/joint-approach-pressrelease\/ <\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>20Med Therapeutics\u00a0announced with its partners\u00a0Ethris GmbH,\u00a0the AO Research Institute Davos\u00a0and\u00a0Paracelsus Medical University\u00a0the receipt of a Eurostars grant to be used to further the development of a novel approach to treating osteoarthritis (OA) by the consortium of companies and institutions. The Eurostars program is managed by the EUREKA organization, which supports highly innovative technologies to bring [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[57,43],"tags":[],"class_list":["post-14971","post","type-post","status-publish","format-standard","hentry","category-ijzersterk-innovatieklimaat","category-innovatieklimaat"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>20MED THERAPEUTICS AND PARTNERS RECEIVE EUROSTARS GRANT FOR THE DEVELOPMENT OF NEW MRNA THERAPEUTICS FOR OSTEOARTHRITIS - hollandbio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/20med-therapeutics-and-partners-receive-eurostars-grant-for-the-development-of-new-mrna-therapeutics-for-osteoarthritis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"20MED THERAPEUTICS AND PARTNERS RECEIVE EUROSTARS GRANT FOR THE DEVELOPMENT OF NEW MRNA THERAPEUTICS FOR OSTEOARTHRITIS - hollandbio\" \/>\n<meta property=\"og:description\" content=\"20Med Therapeutics\u00a0announced with its partners\u00a0Ethris GmbH,\u00a0the AO Research Institute Davos\u00a0and\u00a0Paracelsus Medical University\u00a0the receipt of a Eurostars grant to be used to further the development of a novel approach to treating osteoarthritis (OA) by the consortium of companies and institutions. The Eurostars program is managed by the EUREKA organization, which supports highly innovative technologies to bring [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/20med-therapeutics-and-partners-receive-eurostars-grant-for-the-development-of-new-mrna-therapeutics-for-osteoarthritis\/\" \/>\n<meta property=\"og:site_name\" content=\"hollandbio\" \/>\n<meta property=\"article:published_time\" content=\"2019-08-27T14:23:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-08-27T14:23:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Hollandbio\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:site\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Hollandbio\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/20med-therapeutics-and-partners-receive-eurostars-grant-for-the-development-of-new-mrna-therapeutics-for-osteoarthritis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/20med-therapeutics-and-partners-receive-eurostars-grant-for-the-development-of-new-mrna-therapeutics-for-osteoarthritis\\\/\"},\"author\":{\"name\":\"Hollandbio\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/93e80fd679b3dcaf6e4f264cf909d7dd\"},\"headline\":\"20MED THERAPEUTICS AND PARTNERS RECEIVE EUROSTARS GRANT FOR THE DEVELOPMENT OF NEW MRNA THERAPEUTICS FOR OSTEOARTHRITIS\",\"datePublished\":\"2019-08-27T14:23:29+00:00\",\"dateModified\":\"2019-08-27T14:23:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/20med-therapeutics-and-partners-receive-eurostars-grant-for-the-development-of-new-mrna-therapeutics-for-osteoarthritis\\\/\"},\"wordCount\":267,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"articleSection\":[\"IJzersterk innovatieklimaat\",\"Innovatieklimaat\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/20med-therapeutics-and-partners-receive-eurostars-grant-for-the-development-of-new-mrna-therapeutics-for-osteoarthritis\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/20med-therapeutics-and-partners-receive-eurostars-grant-for-the-development-of-new-mrna-therapeutics-for-osteoarthritis\\\/\",\"name\":\"20MED THERAPEUTICS AND PARTNERS RECEIVE EUROSTARS GRANT FOR THE DEVELOPMENT OF NEW MRNA THERAPEUTICS FOR OSTEOARTHRITIS - hollandbio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\"},\"datePublished\":\"2019-08-27T14:23:29+00:00\",\"dateModified\":\"2019-08-27T14:23:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/20med-therapeutics-and-partners-receive-eurostars-grant-for-the-development-of-new-mrna-therapeutics-for-osteoarthritis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/20med-therapeutics-and-partners-receive-eurostars-grant-for-the-development-of-new-mrna-therapeutics-for-osteoarthritis\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/20med-therapeutics-and-partners-receive-eurostars-grant-for-the-development-of-new-mrna-therapeutics-for-osteoarthritis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"20MED THERAPEUTICS AND PARTNERS RECEIVE EUROSTARS GRANT FOR THE DEVELOPMENT OF NEW MRNA THERAPEUTICS FOR OSTEOARTHRITIS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"name\":\"hollandbio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\",\"name\":\"hollandbio\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"width\":218.664,\"height\":29.659,\"caption\":\"hollandbio\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hollandbio\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hollandbio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/93e80fd679b3dcaf6e4f264cf909d7dd\",\"name\":\"Hollandbio\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"20MED THERAPEUTICS AND PARTNERS RECEIVE EUROSTARS GRANT FOR THE DEVELOPMENT OF NEW MRNA THERAPEUTICS FOR OSTEOARTHRITIS - hollandbio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hollandbio.nl\/en\/nieuws\/20med-therapeutics-and-partners-receive-eurostars-grant-for-the-development-of-new-mrna-therapeutics-for-osteoarthritis\/","og_locale":"en_US","og_type":"article","og_title":"20MED THERAPEUTICS AND PARTNERS RECEIVE EUROSTARS GRANT FOR THE DEVELOPMENT OF NEW MRNA THERAPEUTICS FOR OSTEOARTHRITIS - hollandbio","og_description":"20Med Therapeutics\u00a0announced with its partners\u00a0Ethris GmbH,\u00a0the AO Research Institute Davos\u00a0and\u00a0Paracelsus Medical University\u00a0the receipt of a Eurostars grant to be used to further the development of a novel approach to treating osteoarthritis (OA) by the consortium of companies and institutions. The Eurostars program is managed by the EUREKA organization, which supports highly innovative technologies to bring [&hellip;]","og_url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/20med-therapeutics-and-partners-receive-eurostars-grant-for-the-development-of-new-mrna-therapeutics-for-osteoarthritis\/","og_site_name":"hollandbio","article_published_time":"2019-08-27T14:23:29+00:00","article_modified_time":"2019-08-27T14:23:30+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","type":"image\/png"}],"author":"Hollandbio","twitter_card":"summary_large_image","twitter_creator":"@hollandbio","twitter_site":"@hollandbio","twitter_misc":{"Written by":"Hollandbio","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/20med-therapeutics-and-partners-receive-eurostars-grant-for-the-development-of-new-mrna-therapeutics-for-osteoarthritis\/#article","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/20med-therapeutics-and-partners-receive-eurostars-grant-for-the-development-of-new-mrna-therapeutics-for-osteoarthritis\/"},"author":{"name":"Hollandbio","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/93e80fd679b3dcaf6e4f264cf909d7dd"},"headline":"20MED THERAPEUTICS AND PARTNERS RECEIVE EUROSTARS GRANT FOR THE DEVELOPMENT OF NEW MRNA THERAPEUTICS FOR OSTEOARTHRITIS","datePublished":"2019-08-27T14:23:29+00:00","dateModified":"2019-08-27T14:23:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/20med-therapeutics-and-partners-receive-eurostars-grant-for-the-development-of-new-mrna-therapeutics-for-osteoarthritis\/"},"wordCount":267,"publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"articleSection":["IJzersterk innovatieklimaat","Innovatieklimaat"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/20med-therapeutics-and-partners-receive-eurostars-grant-for-the-development-of-new-mrna-therapeutics-for-osteoarthritis\/","url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/20med-therapeutics-and-partners-receive-eurostars-grant-for-the-development-of-new-mrna-therapeutics-for-osteoarthritis\/","name":"20MED THERAPEUTICS AND PARTNERS RECEIVE EUROSTARS GRANT FOR THE DEVELOPMENT OF NEW MRNA THERAPEUTICS FOR OSTEOARTHRITIS - hollandbio","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/#website"},"datePublished":"2019-08-27T14:23:29+00:00","dateModified":"2019-08-27T14:23:30+00:00","breadcrumb":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/20med-therapeutics-and-partners-receive-eurostars-grant-for-the-development-of-new-mrna-therapeutics-for-osteoarthritis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hollandbio.nl\/en\/nieuws\/20med-therapeutics-and-partners-receive-eurostars-grant-for-the-development-of-new-mrna-therapeutics-for-osteoarthritis\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/20med-therapeutics-and-partners-receive-eurostars-grant-for-the-development-of-new-mrna-therapeutics-for-osteoarthritis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.hollandbio.nl\/en\/"},{"@type":"ListItem","position":2,"name":"20MED THERAPEUTICS AND PARTNERS RECEIVE EUROSTARS GRANT FOR THE DEVELOPMENT OF NEW MRNA THERAPEUTICS FOR OSTEOARTHRITIS"}]},{"@type":"WebSite","@id":"https:\/\/www.hollandbio.nl\/en\/#website","url":"https:\/\/www.hollandbio.nl\/en\/","name":"hollandbio","description":"","publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hollandbio.nl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.hollandbio.nl\/en\/#organization","name":"hollandbio","url":"https:\/\/www.hollandbio.nl\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","contentUrl":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","width":218.664,"height":29.659,"caption":"hollandbio"},"image":{"@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hollandbio","https:\/\/www.linkedin.com\/company\/hollandbio\/"]},{"@type":"Person","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/93e80fd679b3dcaf6e4f264cf909d7dd","name":"Hollandbio"}]}},"_links":{"self":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/14971","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/comments?post=14971"}],"version-history":[{"count":0,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/14971\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/media?parent=14971"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/categories?post=14971"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/tags?post=14971"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}